Format

Send to

Choose Destination
J Antimicrob Chemother. 2005 Mar;55(3):283-8. Epub 2005 Feb 10.

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

Author information

1
Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA. Judith.steenbergen@cubist.com

Abstract

Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.

PMID:
15705644
DOI:
10.1093/jac/dkh546
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center